Advances in Our Understanding of DystoniaPathophysiology and Treatment Options
Dystonia is characterized by involuntary muscle contractions causing twisting movements and abnormal postures. 1 It is clinically and etiologically heterogeneous and is most usefully classified by etiology as either primary or secondary dystonia. In primary dystonias, dystonia is the only neurologic sign (except for tremor), and there is no evidence of an acquired cause or of any neurodegenerative process. In secondary dystonias, dystonia occurs together with other neurologic symptoms and is due to acquired causes or to neurodegenerative disease. An intermediary category is termed 'dystonia plus syndromes,' and consists of disorders in which there is no acquired etiology or neurodegeneration, but in which there are neurologic symptoms other than dystonia.
This category includes dopa-responsive dystonia (DRD/DYT5), myoclonus dystonia (MD/DYT11) and rapid-onset dystonia-parkinsonism (RDP/DYT12) (see Table 1 : Classification of Dystonia). Primary dystonia is subdivided into early-onset and adult-onset forms. Early-onset primary dystonias typically initially affect a limb and subsequently spread, frequently becoming generalized. Genes have been identified in two forms of early-onset primary dystonia: DYT1 and DYT6. Late-onset primary dystonia typically occurs in either cervical, cranial, or brachial muscles, and remains focal or segmental. Adult-onset focal dystonia (with cervical dystonia as the most common form) is far more common than early-onset primary dystonia.
Although the pathophysiology of dystonia remains incompletely understood, advances in two major areas of research over the past two decades have led to important insights into mechanisms of dystonia. commonly due to lesions of the basal ganglia, specifically the putamen or globus pallidus. However, the absence of neurodegeneration in primary dystonia, as well as observations that lesions of brain regions other than the basal ganglia can lead to secondary dystonia, have led to the concept of dystonia as a neuro-functional disorder, i.e. a disorder characterized by abnormal connectivity that may occur in a structurally normal appearing brain. Dystonia symptoms may occur, then, due to developmental abnormalities resulting in synaptic dysfunction or increased plasticity of motor circuits; dystonia is therefore considered to be a motor system disorder rather than a disease of a particular motor structure. Accordingly, studies using various investigative tools have yielded evidence of dysfunction in almost every region of the central nervous systm (CNS) involved in motor control and sensorimotor integration, including cortex, brainstem, cerebellum, and spinal cord. 
Early-onset Torsion Dystonia Animal Models
Two types of mouse models of DYT1 have been produced: heterozygous knock-in mice, in which the GAG mutation is introduced into the endogenous mouse torsinA gene, and transgenic mice, in which the human mutant torsinA gene is inserted into the mouse genome and over-expressed via genetic promoters. Neither of these models has overt dystonic features, although they both manifest more subtle motor abnormalities, including hyperactivity and deficits in beam walking. 12, 13 Another transgenic mouse model has impaired motor-learning in a similar fashion to 14 motor sequence learning deficits found in DYT1 non-manifesting carriers. 15 Mice that are either homozygous knock-in or knock-out for the mutation die at birth, whereas a knock-down mouse model in which expression of torsinA is reduced has a phenotype similar to the heterozygous knock-in mice. 16 This suggests that the pathogenic deletion produces a loss of function of TorsinA. The loss of function may be the result of a dominant negative effect, in which the mutant protein interferes with the wild-type protein.
DYT6 Dystonia
DYT6 dystonia is characterized by a relatively early but broad age of onset (mean 16 years, range five to 49 years). The body regions first affected include the arm, cranial muscles (larynx, tongue, and facial muscles), and neck. In contrast to DYT1, onset at the leg is uncommon.
The dystonia usually progresses, but the degree of progression is variable. For most patients with DYT6 dystonia, disability is due to cranial and cervical dystonia, including significant speech difficulties. As in DYT1, DYT6 is inherited in an autosomal dominant pattern with reduced penetrance. The DYT6 gene, THAP1, is the most recently identified dystonia gene. 17 The initial report was of two mutations in the THAP1 gene causing DYT6 dystonia in five families. Subsequent genetic screening studies in families with early-onset, non-DYT1, non-focal primary dystonia identified 11 additional THAP1 mutations in families of diverse ancestries, suggesting that mutations in THAP1 may underlie a substantial proportion of dystonia in early-onset non-DYT1 families, particularly in those with affected cranial muscles. 18, 19 The THAP1 protein is a sequence-specific DNA binding factor that regulates 
Dystonia Plus Syndromes Dopa-responsive Dystonia
The classic form of dopa-responsive dystonia (DRD/DYT5) is an early-onset dystonia presenting in childhood (five to six years of age) with dystonia of the lower extremities, and a diurnal pattern to the symptoms. Arm dystonia, hyperreflexia, and parkinsonism are other common features. The hallmark feature of this disorder is a dramatic and sustained resolution of dystonia symptoms in response to low-dose levodopa therapy. The autosomal dominant form of DRD is caused by mutations in the GCH1 gene. GCH1 is required for the synthesis of tetrahydrobiopterin, an essential cofactor for tyrosine hydroxylase, which is the rate-limiting enzyme in dopamine synthesis. Penetrance is incomplete and is gender related, with females manifesting dystonia two to four times more frequently than males. 20 Over 100 different GCH1 mutations have been identified, 21 but GCH1 mutations are not found in approximately 25% of patients with DRD. 22 Recessive genetic causes account for some of the mutation negative cases, but a small proportion of DRD cases remain unexplained. 22 There are several autosomal recessive forms of DRD to be found, which are due to varying mutations in genes encoding other enzymes involved in dopamine synthesis, including tyrosine hydroxylase (TH), 23 6-pyruvoyltetrahydropterin synthase (6-PTPS), 24 and sepiapterin reductase. 25 Typically, the clinical picture in these conditions is different from GCH1 DRD, with infantile-onset severe neurologic symptoms, including hypotonia, severe bradykinesia, drooling, ptosis, miosis, oculogyria, cognitive impairment, and seizures. 22 Another important autosomal recessive cause of the DRD phenotype are mutations in the 'juvenile' parkinsonism parkin gene. 22, 26, 27 Generally the presence of early prominent parkinsonism and severe dyskinesias favors parkin mutations.
Myoclonus Dystonia
Myoclonus dystonia (MD) (DYT11 and DYT15) is characterized by prominent early-onset myoclonus with or without dystonia. Symptom onset is typically in the first or second decade, and symptoms tend to plateau in adulthood. The neck and arms are the most commonly there may be a sudden worsening. 32, 33 The gene has been identified as ATP1A3, which codes for the sodium potassium transporting 34 ATPase alpha-3 chain, a catalytic subunit of the sodium-potassium pump. non-dystonic subjects. 38, 39 Studies of sensory processing in dystonia patients using spatial discrimination thresholds (SDT) or temporal discrimination thresholds (TDT) (tests of discrimination between two close-interval sensory stimuli) have found abnormal SDTs and TDTs in patients with adult-onset sporadic primary dystonia and in their unaffected relatives. 40, 41 Notably, a recent study comparing SDT and TDT as potential endophenotypes found that TDT was a much more reliable measurement. 42 'Double pulse' repetitive transmagnetic stimulation (rTMS) studies have demonstrated evidence of decreased cortical inhibition and increased excitability in various forms of dystonia, including in both DYT1 dystonia patients and DYT1 non-manifesting carriers, 43 and in the hand motor cortex in both focal hand dystonia patients as well as in patients with blephorospasm. 44 Interestingly, in two TMS studies in patients with psychogenic dystonia, the abnormalities of cortical inhibition seen in patients with organic dystonia were also seen in the psychogenic dystonia patients. 45, 46 rTMS studies are also used as probes of cortical plasticity in dystonia.
In these studies, conditioning protocols are used that produce long-term changes in cortical excitability, i.e. either decreased or increased excitability, depending on the frequency of the repetitive pulses. Motor excitability is assessed by measuring the EMG response to a standard single TMS pulse before and at various times after the plasticity-inducing protocol. These studies have found evidence supportive of aberrant plasticity in patients with various forms of dystonia, including focal hand dystonia and in DYT1 manifesting and non-manifesting carriers. 47, 48 For example, in a paired associative stimulation (PAS) protocol, a stimulus to the median nerve is paired with a subsequent TMS pulse to the contralateral hand motor cortex.
With this protocol, healthy subjects have normal facilitation in the median-innervated abductor pollicis brevis (APB) muscle and no facilitation in the ulnar-innervated first dorsal interosseus (FDI) muscle. By contrast, patients with focal hand dystonia have enhanced facilitation in both the APB as well as the ulnar innervated FDI, 49, 50 demonstrating a loss of topographic specificity. In a TMS study examining cortical inhibition and cortical plasticity in psychogenic dystonia, abnormalities of cortical inhibition were confirmed in the psychogenic patients, but only patients with organic dystonia had abnormal plasticity. Further support for maladaptive sensorimotor processing is provided by oxygen-labeled water PET studies in DYT1 gene carriers, in which testing was performed in two scenarios: one assessed brain activation during a simple motor task and the other assessed activation in a non-motor audio-visual setting. Not surprisingly, differences were noted between manifesting and non-manifesting carriers. In the non-motor condition, both had abnormal increases in network activity, with a pattern of increased activation involving the sensorimotor cortex, dorsal premotor cortex, supplementary motor area, and cerebellum. By contrast, when performing a motor task, only the manifesting carriers had increased activation. This dissociation between motor and non-motor patterns of activation suggests an underlying genotype-related abnormality in the integration of audio-visual input with sensorimotor network activity, with additional motor-activated dysfunction in those patients with clinical dystonia. 55 The basis for this difference, at least in the genetic groups of DYT1 and DYT6 dystonia, may relate to developmental structural defects in the cerebello-thalamo-cortical pathway.
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Functional and Anatomic Motor Circuit Abnormalities
The cerebellum has been suggested to have a prominent role in modulating cortical plasticity, [56] [57] [58] Conversely, when acetylcholine was pharmacologically increased, the plasticity abnormalities were seen in mice expressing normal torsinA and in non-transgenic controls. These findings support the notion that unbalanced cholinergic transmission plays a pivotal role in the abnormal synaptic plasticity of DYT1 dystonia, and also provide a clue to the ability of anticholinergic drugs to improve dystonia symptoms. 64 
Gamma-aminobutyric Acid
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter and is also important in shaping plastic responses of the CNS to somatosensory and other stimuli, including the maintenance and plasticity of cortical receptive fields. Drugs that potentiate GABA, such as benzodiazepines and baclofen, are modestly effective against dystonia symptoms. In animal studies, application of the GABA antagonist bicuculline to the motor cortex of monkeys produces abnormal movements similar to task-specific dystonia. 65 Studies measuring GABA levels in the cortex and striatum of patients with adult-onset primary dystonia found decreased GABA levels in cortical and subcortical regions contralateral to the dystonic limb.
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Treatment of Dystonia
Pharmacologic Treatment
The is also frequently used to treat laryngeal dystonia (spasmodic dysphonia), and focal limb dystonia. Aside from its direct peripheral effect of weakening affected muscles, botulinum toxin injections may also reduce afferent feedback from affected muscles, potentially normalizing the abnormal plastic changes in the CNS. Accordingly, DTI studies have shown normalization of white-matter abnormalities after botulinum toxin treatment in some dystonia patients, 67 and in TMS studies in cervical dystonia patients treated with botulinum toxin, abnormalities in hand motor cortex were reversed. 68 
Neurosurgical Treatment
Historically, dsytonia patients were treated surgically with pallidotomy or thalamotomy. These lesional surgeries provided significant benefit to dystonia symptoms in some cases, but also frequently caused In secondary dystonia, data regarding the efficacy of DBS is scant and, with one recent exception, consists only of case reports or small cohorts with heterogeneous forms of secondary dystonia, with results ranging from no benefit to dramatic improvement. Most recently, Vidailhet et al. reported a multicenter prospective pilot study of bilateral pallidal DBS in 13 adults with dystonia-choreoathetosis cerebral palsy, and the response in these patients was again heterogeneous. 71 The question of whether DBS should be considered as a treatment option for secondary dystonia therefore also remains open.
In conclusion, dystonia is a neurofunctional disorder characterized by alterations at various levels and at multiple points along the sensorimotor circuit. Multiple causes can cause these disruptions 
